-
In a Phase 3b clinical trial, Novo Nordisk's (NYSE:NVO) Ryzodeg (insulin degludec/insulin aspart) administered twice daily provided successful glycemic control with fewer injections than a basal-bolus regimen and reduced rates of hypoglycemia. The study failed to achieve its primary endpoint of non-inferiority, however.
- Ryzodeg is a combination of two distinct insulin analogs (70% insulin degludec and 30% insulin aspart). It is the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.